Activation of cannabinoid receptor 2 attenuates Angiotensin II-induced atrial fibrillation via a potential NOX/CaMKII mechanism
Department of Cardiovascular Surgery, General Hospital of Northern Theater Command, Shenyang, Liaoning, China
Postgraduate College, China Medical University, Shenyang, Liaoning, China
Abstract
Background
Atrial fibrillation (AF) is the most frequent arrythmia managed in clinical practice. Several mechanisms have been proposed to contribute to the occurrence and persistence of AF, in which oxidative stress plays a non-negligible role. The endocannabinoid system (ECS) is involved in a variety physiological and pathological processes. Cannabinoid receptor 1 (CB1R) and cannabinoid receptor 2 (CB2R) are expressed in the heart, and studies have shown that activating CB2R has a protective effect on the myocardium. However, the role of CB2R in AF is unknown.
Materials and methods
Angiotensin II (Ang II)-infused mice were treated with the CB2R agonist AM1241 intraperitoneally for 21 days. Atrial structural remodeling, AF inducibility, electrical transmission, oxidative stress and fibrosis were measured in mice.
Results
The susceptibility to AF and the level of oxidative stress were increased significantly in Ang II-infused mice. In addition, nicotinamide adenine dinucleotide phosphate oxidase 2 (NOX2), NOX4, and oxidized Ca2+/calmodulin-dependent protein kinase II (ox-CaMKII) were highly expressed. More importantly, treatment with AM1241 activated CB2R, resulting in a protective effect.
Conclusion
The present study demonstrates that pharmacological activation of CB2R exerts a protective effect against AF via a potential NOX/CaMKII mechanism. CB2R is a potential therapeutic target for AF.
Untitled section
Keywords: atrial fibrillation, endocannabinoid system, cannabinoid receptor 2, nicotinamide adenine dinucleotide phosphate oxidase, Ca2+/calmodulin-dependent protein kinase II, oxidative stress
Article notes
Untitled section
Received 2022 Jun 13; Accepted 2022 Sep 29; Collection date 2022.
Introduction
Atrial fibrillation (AF), the most common arrhythmia in clinical practice, affects nearly 2% of the general population and is associated with a pronounced increase in the incidence of heart disease and death (1). During recent decades, our understanding of the mechanisms driving the pathogenesis and maintenance of AF has increased considerably. Atrial remodeling, including electrophysiological changes and structural remodeling, is the main cause of the occurrence and persistence of AF (2). Oxidative stress has been investigated as a potential essential link between AF and atrial remodeling (3). Oxidative stress is an imbalance between oxidants and antioxidants in favor of the former, resulting in excess reactive oxygen species (ROS) accumulation and leading to cellular damage. Numerous studies have shown that excess ROS directly affect ion channels and cause electrical remodeling (4). In addition, research evidence suggests that hydroxyl radicals, a type of ROS, can alter myofibrillar protein structure and function and further contribute to structural remodeling, which is a feature of atrial fibrosis (5). Given this, reducing oxidative stress may be an attractive target for the treatment of AF.
The endocannabinoid system (ECS) consists of endogenous ligands, enzymes for synthesis, degradation and transport, and cannabinoid receptors (CBRs). Cannabinoid receptor 1 (CB1R) was cloned from a rat cerebral cortex cDNA library in 1987 and characterized as the specific membrane receptor of a cannabinoid compound 1 year later. It was not until 5 years later that another cannabinoid receptor was found in macrophages of the spleen and named cannabinoid receptor 2 (CB2R). The endogenous ligands anandamide (AEA) and 2-arachidonoylglycerol (2-AG) were discovered in 1992 and 1995 (6). The ECS has been reported to play an important role in the pathogenesis and progression of diseases (7), and pharmacological inhibition of CB1R or activation of CB2R exerts cardioprotective effects (8). Unlike CB1R, which is mainly distributed in the central nervous system, CB2R has gained attention as an important therapeutic target due to its lack of psychoactivity. Moreover, it has been confirmed in various animal models of atherosclerosis and myocardial ischemia/reperfusion injury that CB2R activation by natural and synthetic agonists shows antioxidative effects (9). However, little is known about the role of CB2R in AF, and we were curious as to whether it can decrease oxidative stress in AF.
Mitochondria, dynamic organelles regulated by fission and fusion, are major sources of ROS (10). Nicotinamide adenine dinucleotide phosphate (NADPH) oxidase (NOX) is the most important enzyme in oxidative stress, and it has been reported that Ca2+/calmodulin-dependent protein kinase II (CaMKII), a well-described serine-threonine kinase related to cardiovascular diseases (11), can be oxidized by NOX at methionines 281 and 282 to form oxidized CaMKII (ox-CaMKII) (12). In addition, a series of studies have confirmed that ox-CaMKII plays a proarrhythmic role in both AF and sinoatrial node dysfunction and functions upstream of ROS by inducing mitochondrial damage (13–16).
Therefore, the CB2R agonist AM1241 was used as an adjuvant to reduce the susceptibility of AF in Angiotensin II (Ang II)-infused mice. In addition, the involvement of the NOX/CaMKII mechanism in the protective action of AM1241 was evaluated.
Materials and methods
Animals and treatment
Eight-week-old male C57BL/6 mice (HUAFUKANG Bioscience Co., Ltd., Beijing, China) were kept under standard housing conditions. After a 1-week acclimatization period, the mice were randomly assigned to 5 groups (n = 15 for each group): the control group, the Ang II group, the Ang II + vehicle (Veh) group, the Ang II + AM1241 group, and the Ang II + AM630 group. Ang II (2,000 ng/kg/min) (A1042, APExBIO, Houston, TX, USA) was subcutaneously infused into the mice for 3 weeks with osmotic pumps (Alzet model 2004; Durect, CA, USA). The control group underwent sham operation. The CB2R agonist AM1241 (S1544, Selleck Chemicals, Houston, TX, USA) and CB2R antagonist AM630 (HY-15421, MedChemExpress, Monmouth Junction, NJ, USA) were dissolved in solvents containing DMSO, Tween-20 and PBS (1:1:8). The concentration of AM1241 was 20 mg/kg, the concentration of AM630 was 3 mg/kg, and the solvent was injected into the Ang II + Veh group (8). The drug injection volume per day was 0.1 mL per mouse for 21 days. For the first time, the drugs were administered intraperitoneally for 1 h before the pumps were implanted, and then the injection was performed at the same time every day.
Blood pressure measurement and echocardiographic measurement of the left atrium
The blood pressure (BP) of mice was measured before and at the end of treatment with a tail-cuff system (BP-2010, Softron Biotechnology, Beijing, China). Each measurement was repeated three times, and the average BP was calculated. On the 21st day post-Ang-II infusion, echocardiography was performed with a high-resolution ultrasound imaging system (D700, Vinno, Suzhou, China). Mice were anesthetized with 1.5% isoflurane. The left atrium (LA) movement was recorded on the parasternal long-axis view, and the left atrium diameter (LAD) was measured at the left ventricular end systole.
Atrial fibrillation stimulation
Surface electrocardiogram (ECG) was recorded in anesthetized mice (1% pentobarbital sodium) using PowerLab monitoring systems and LabChart v7 software (ADInstruments, Castle Hill, Australia). A 1.1 F octapolar electrode catheter (Transonic Scisense Inc., Ontario, Canada) was inserted into the right atrium via the jugular vein. The inducibility of AF was evaluated by bust stimulation (iWorx System Inc., Dover, NH, USA) for 2 s starting with a cycle length (CL) of 40 ms and decreasing in each burst by a 2 ms decrement to a CL of 20 ms (17). The burst pacing protocols were repeated three times after stabilization for 5 min, and AF was considered to be inducible if 2 or 3 bursts evoked an AF episode for at least 2 s on the ECG. AF duration was defined as the total period of time from the end of burst pacing to the first P wave detected in each individual mouse (18).
Atrial electrophysiological mapping
Atrial electrophysiological mapping was performed according to a previous study (19). In brief, the mice were placed on the operating table after anesthetizing and ventilation (Taimeng Technology, Chengdu, China). The thorax was opened, and the LA was exposed. A 64-electrode microelectrode array was placed on the surface of the LA. A 64-channel electrophysiological mapping system (MappingLab Inc., UK) was used to record electrograms. The mean conduction velocity and absolute inhomogeneity were acquired using EMapScope5 software (MappingLab Inc., UK). Then, the mice were sacrificed immediately for blood and heart samples.
Serological experiment
The serum samples were separated by centrifugation in anticoagulant tubes (1,000 g, 10 min). The activity of superoxide dismutase (SOD) and the contents of malondialdehyde (MDA), glutathione (GSH), Ang II, and aldosterone (ALD) were determined by colorimetric reagent kits from the Nanjing Jiancheng Bioengineering Institute.
Histological staining analysis
Atrial paraffin sections at 5 μm were deparaffinized and hydrated and then stained by H&E staining (KGA224, KeyGEN Bio TECH Corp., Jiangsu, China) and Masson’s trichrome staining (BA4079, Baso Diagnostics Inc., Zhuhai, China). The pictures were captured by a UB203i microscope (Aopu Technology, Chongqing, China). To visualize the ROS in the atrium, frozen atrial sections at 8 μm were incubated with 20 μM dihydroethidium operating fluid (KGAF019, KeyGEN Bio TECH Corp., Jiangsu, China) at room temperature for 30 min. All fluorescence images were taken by a Nikon C2 Plus confocal microscope (Nikon, Tokyo, Japan). At least 3 fields from each sample were randomly selected for quantitative analysis via ImageJ software.
Transmission electron microscopy
Atrial samples (1 mm3 blocks) were fixed with 2.5% glutaraldehyde at 4°C overnight and then postfixed in 1% osmium tetroxide for 1 h. The blocks were dehydrated with a graded series of ethanol solutions and embedded in epoxy resin. Thereafter, they were cut into 60 nm ultrathin sections (EM UC7, Leica, Vienna, Austria), which were subsequently observed with a transmission electron microscope (TEM) (HI7700, Hitachi, Tokyo, Japan). The images were analyzed using ImageJ software.
Western blot analysis
Total proteins were prepared using RIPA lysis buffer (abs9225, Absin, Shanghai, China) containing 1% protease inhibitor (BP101, Bio-Platform, Shanghai, China). Tissue lysates were separated by electrophoresis and transferred onto polyvinylidene difluoride (PVDF) membranes (IPVH00010, Merck Millipore Ltd., MA, USA) by the sandwich method. The membranes were incubated with primary antibodies against CB2R (PA569179, Thermo Fisher, Shanghai, China), CaMKII (4436, Cell Signaling Technology, Boston, MA, USA), and ox-CaMKII (36254, GeneTex, Southern California, CA, USA) overnight at 4°C followed by a horseradish peroxidase peroxidase-conjugated secondary antibody for 1 h at room temperature. The blots were detected by enhanced chemiluminescence (P10300, NCM, Suzhou, China) and were scanned by a Tanon image analysis system (5200, Tanon, Shanghai, China).
Statistical analysis
All data are presented as the mean ± SEM (standard error of the mean). Differences were assessed with Student’s t test or one-way analysis of variance (ANOVA), followed by Bonferroni post hoc test (v9.0, GraphPad Software, San Diego, CA, USA). A value of P < 0.05 was considered to indicate statistical significance.
Results
Under Angiotensin II stimulation, the RAAS was activated, and blood pressure rose
Before the treatment, there were no significant differences in BP among the five groups. After 21 days of treatment, there was still no significant change in the control group. However, the BPs of the other four groups rose significantly compared with that of the control group in the same period (Figure 1A). Serological examination showed that the levels of Ang II and ALD in the four groups other than the control group were higher than those before treatment (Figures 1B,C). AM1241 and AM630 did not affect BP or the levels of Ang II and ALD.
Administration of AM1241 reduced the inducibility of atrial fibrillation in Angiotensin II-infused mice
Compared to those in the control mice, the inducibility and duration of AF in Ang II-infused mice were increased significantly. However, after administration of AM1241, the inducibility and duration decreased, while they did not change significantly after AM630 treatment (Figures 2A–C). In addition, the electrophysiological mapping experiment showed that Ang II significantly decreased the mean conduction velocity and increased absolute inhomogeneity. These effects were also suppressed by AM1241 administration, and AM630 treatment did not affect the above changes (Figures 2D–F). Next, the echocardiographic data showed that AM1241 administration attenuated Ang II-induced LA chamber enlargement, and AM630 treatment did not (Figures 2G,H).
Administration of AM1241 attenuated oxidative stress in the atrial tissue of Angiotensin II-infused mice by activating cannabinoid receptor 2
Immunoblotting of atrial tissue showed that the expression of CB2R was slightly decreased in Ang II-infused mice but increased significantly after administration of AM1241 and AM630 (Figure 3A). MDA is a main lipid peroxidation product that reflects the level of oxidative stress. GSH and SOD are the major antioxidants. Ang II-infused mice showed elevated MDA levels, reduced GSH levels and reduced SOD enzyme activity. The adverse outcomes were remarkably reversed by the addition of AM1241 (Figures 1D–F). Later, oxidative stress in LA was detected. Fluorescence staining demonstrated that the mean ROS intensity was increased in Ang II-infused mice but decreased after treatment with AM1241 (Figures 3B,C). In addition, western blot analysis showed that the levels of ox-CaMKII, NOX2 and NOX4 were increased in the Ang II-infused mice but were decreased by AM1241 treatment (Figures 3D,E). However, no distinct changes occurred after AM630 administration.
Administration of AM1241 attenuated mitochondrial damage in Angiotensin II-infused mice
Morphological changes in mitochondria in LA were detected by TEM. As shown in Figure 4A, mitochondria were intact in the control group, and the cristae were in order and clear. After damage by Ang II, most of the mitochondria were swollen and even cavitated, and the cristae were deformed and dissolved. The occurrence of swollen mitochondria increased (Figure 4B), and the length ratio of the cristae membrane to mitochondrial outer membrane decreased significantly (Figure 4C). After AM1241 administration, there were fewer disorganized mitochondria, and the pathological changes were attenuated. Fission is an important feature of mitochondrial dynamics, and phosphorylation of Drp1 Ser616 promotes mitochondrial fission. In Ang II-infused mice, western blotting confirmed the increased phosphorylation of Drp1 at Ser616 (Figure 4D). Notably, AM1241 showed deterrent effects on Drp1 phosphorylation, and there was no significant difference in the above changes between the Ang II + AM360 group and Ang II group.
Administration of AM1241 attenuated atrial fibrosis in Angiotensin II-infused mice
Atria from Ang II-infused mice displayed large fibrotic areas, as indicated by Masson’s trichrome staining and H&E staining, while treatment with AM124 alleviated fibrosis (Figures 5A–C). Moreover, significant atrial fibrosis was evidenced by western blotting analysis of TGF-β, MMP, collagen I and collagen III, but the expression of these proteins was restored in mice in the Ang II + AM1241 group (Figure 5D). As with previous results, AM630 did not ameliorate the impact of Ang II.
Discussion
As the global life expectancy increases, the prevalence of AF in the general population is rising sharply. Thus, AF is becoming an urgent public health issue. In addition, AF may seriously affect patients’ quality of life, as it is related to serious complications, such as stroke, heart failure, and cardiac arrest, which result in increased morbidity, mortality and health care costs (20). Therefore, effective treatment of AF is critically needed. AF treatment is largely based on catheter ablation. The currently available pharmacotherapies for AF have poor efficacy, mainly because they are not directed at the molecular cause of AF (21). Oxidative stress and fibrosis are indispensable pathogenic mechanisms in AF. The experimental results showed that the susceptibility of Ang II-infused mice to AF was significantly increased and that oxidative stress and fibrosis were also altered. Notably, these changes were reversed after treatment with the CB2R receptor-specific agonist AM1241, while the adverse consequences of Ang II were not improved after administration of the CB2R antagonist AM630.
Angiotensin II is the main regulator of cardiac oxidative stress and increases the production of ROS in the cardiovascular system by activating membrane-bound NOX, endoplasmic reticulum stress and mitochondrial oxidative stress (22). ROS can ultimately cause myocardial fibrosis and promote the appearance and persistence of AF. This creates a dangerous positive feedback loop, predisposing patients to AF and thus further fibrosis (23). Moreover, Professor Anderson found that targeted loss of ox-CaMKII in oxidation-resistant CaMKII MMVV mice [a mouse model whose methionine pair (281/282) was replaced by valine] was sufficient to prevent the proarrhythmic response of Ang II in AF (16). They reasoned that CaMKII is an upstream signal of ROS and can be activated by NOX (12). In our study, the expression of NOX2 and NOX4 was increased in the Ang II-infused mice, and ox-CaMKII also changed accordingly, resulting in mitochondrial damage; this enhanced oxidative stress and fibrosis and ultimately increased the susceptibility to AF.
The ECS is an intricate and heterogeneous signaling network composed of (i) endogenous cannabinoids (eCBs) such as AEA and 2-AG and other cannabimimetic ligands, e.g., oleoylethanolamide and stearoylethanolamine; (ii) metabolic enzymes such as fatty acid amide hydrolase (FAAH), monoacylglycerol lipase (MAGL) and other enzymes that regulate eCBs; and (iii) the G protein-coupled receptors CB1R and CB2R (6). The interactions among them controls the activity level of the ECS, which plays a vital role in pathophysiology during each stage of life (24). In the cardiovascular system, the expression of CBRs is not high, and it is still unclear what role the ECS plays in the physiological process, but under pathological conditions, the expression of ECS-related components undergoes dramatic changes. Sugamura et al. found that the levels of AEA and 2-AG in blood samples of patients with coronary heart disease were significantly increased and that the expression of CB1R was increased in coronary atherosclerotic plaques (25). Interestingly, in patients with ischemic cardiomyopathy, the expression of CB1R in myocardial tissue is increased, and the expression of CB2R is decreased (26). Moreover, in mouse models, inhibition of CB1R or activation of CB2R alleviates quetiapine (27) or clozapine-induced (28) myocardial damage. Considering the possible undesirable side effects of CB1R modulators (9), the current experiment was carried out for CB2R. We hypothesized that the expression of CB2R would decrease with continuous Ang II infusion, while pharmaceutical agonism of CB2R would reduce susceptibility to AF. Ultimately, our results fully verified this conjecture.
Cannabinoid receptor 2 (CB2R) activation has an obvious protective effect on the myocardium. It has been confirmed that activation of CB2R reduces necroptosis of the myocardium induced by ethanol (8). It has also been reported that CB2R deficiency impairs regulation of immune activity and apoptosis, resulting in myocardial maladaptation to pressure overload (29). On the other hand, Danielle et al. perfused rat hearts with the CB2R agonist CB13 in a Langendorff setup and found that CB13 inhibited atrial remodeling caused by tachyarrhythmias (30). In addition, Meeran et al. confirmed that the activation of CB2R had antioxidant, anti-inflammatory and anti-apoptotic effects in rats with myocardial infarction induced by isoproterenol and chronic cardiotoxicity induced by doxorubicin (31, 32). In the current study, considering that Ang II-induced myocardial injury is mainly caused by excessive oxidative stress, we sought to elucidate CB2R-related antioxidant stress pathways. In a series of studies on renal dysfunction, CB2R was found to modulate the expression of NOX (33). However, CB2R has not been studied in the context of myocardial protection, let alone in AF. As expected, after AM1241 treatment, CB2R expression was increased, NOX expression and downstream ox-CaMKII expression were decreased, mitochondrial damage was alleviated, the content of ROS was decreased, and the degree of fibrosis was decreased. Finally, the myocardial conduction velocity increased, and the susceptibility to AF was reduced.
Conclusion
In summary, we found that in Ang II-infused mice, susceptibility to AF was reduced by pharmacological activation of CB2R, and the signaling pathway involved NOX/CaMKII (Figure 6). Since the onset and persistence of AF are inseparable from oxidative stress, we believe that CB2R will become a potential therapeutic target for the treatment of AF.
Nevertheless, our research had some limitations. More accurate knockout, overexpression, and other interventions for in-depth research on the molecular mechanism are needed. Although the Ang II-induced mouse model of AF has been widely used and is representative (34), the role of the endocannabinoid system in AF should be validated in more animal models, such as transverse aortic constriction (TAC) mice. In addition, AM1241 is not a myocardial-specific CB2R agonist, and it is difficult to rule out the possibility that the drug affected the heart through its effects on other systems. Research on myocardial-specific CB2R agonists is urgently needed.
Although the current study was performed only on an Ang II-induced mouse model, the positive results are very promising, and the potential psychiatric side effects of CB1R were avoided. We believe CB2R agonists will be beneficial for the treatment of AF.
Data availability statement
The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.
Ethics statement
The animal study was reviewed and approved by the Animal Care Committee of General Hospital of Northern Theater Command.
Funding
This work was supported by grants from the National Natural Science Foundation of China (81970310, 82070239, and 82170328), the Natural Science Foundation of Liaoning Province (2020-MS-036), and the Young Talent Fund of the Military Science and Technology Project (18-JCJQ-QT-018).
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcvm.2022.968014/full#supplementary-material
References
Untitled section
References
- 1.Lippi G, Sanchis-Gomar F, Cervellin G. Global epidemiology of atrial fibrillation: an increasing epidemic and public health challenge. Int J Stroke. (2021) 16:217–21. 10.1177/1747493019897870
- 2.Nattel S, Heijman J, Zhou L, Dobrev D. Molecular basis of atrial fibrillation pathophysiology and therapy: a translational perspective. Circ Res. (2020) 127:51–72. 10.1161/CIRCRESAHA.120.316363
- 3.Ren XM, Wang XF, Yuan MC, Tian C, Li HL, Yang XY, et al. Mechanisms and treatments of oxidative stress in atrial fibrillation. Curr Pharm Des. (2018) 24:3062–71. 10.2174/1381612824666180903144042
- 4.Sagris M, Vardas EP, Theofilis P, Antonopoulos AS, Oikonomou E, Tousoulis D. Atrial fibrillation: pathogenesis, predisposing factors, and genetics. Int J Mol Sci. (2021) 23:174417. 10.1016/j.ejphar.2021.174417
- 5.Babušíková E, Kaplán P, Lehotský J, Jeseňák M, Dobrota D. Oxidative modification of rat cardiac mitochondrial membranes and myofibrils by hydroxyl radicals. Gen Physiol Biophys. (2004) 23:327–35.
- 6.Tang XR, Liu Z, Li XQ, Wang J, Li LL. Cannabinoid receptors in myocardial injury: a brother born to rival. Int J Mol Sci. (2021) 22:6886. 10.3390/ijms22136886
- 7.Hu Y, Tao Y, Hu J. Cannabinoid receptor 2 deletion deteriorates myocardial infarction through the down-regulation of AMPK-mTOR-p70S6K signaling-mediated autophagy. Biosci Rep. (2019) 39:BSR20180650. 10.1042/bsr20180650
- 8.Liu XC, Zhang DG, Dong XR, Zhu RZ, Ye YH, Li LL, et al. Pharmacological activation of CB2 receptor protects against ethanol-induced myocardial injury related to RIP1/RIP3/MLKL-mediated necroptosis. Mol Cell Biochem. (2020) 474:1–14. 10.1007/s11010-020-03828-1
- 9.Karimian Azari E, Kerrigan A, O’Connor A. Naturally occurring cannabinoids and their role in modulation of cardiovascular health. J Diet Suppl. (2020) 17:625–50. 10.1080/19390211.2020.1790708
- 10.Meyer JN, Leuthner TC, Luz AL. Mitochondrial fusion, fission, and mitochondrial toxicity. Toxicology. (2017) 391:42–53. 10.1016/j.tox.2017.07.019
- 11.Cao L, Chen YL, Lu L, Liu YH, Wang YW, Fan JQ, et al. Angiotensin II upregulates fibroblast-myofibroblast transition through Cx43-dependent CaMKII and TGF-beta1 signaling in neonatal rat cardiac fibroblasts. Acta Biochim Biophys Sin. (2018) 50:843–52. 10.1093/abbs/gmy090
- 12.Wang Q, Quick AP, Cao S, Reynolds J, Chiang DY, Beavers D, et al. Oxidized CaMKII (Ca(2+)/calmodulin-dependent protein kinase II) is essential for ventricular arrhythmia in a mouse model of duchenne muscular dystrophy. Circ Arrhythm Electrophysiol. (2018) 11:e005682. 10.1161/CIRCEP.117.005682
- 13.Swaminathan PD, Purohit A, Soni S, Voigt N, Singh MV, Glukhov AV, et al. Oxidized CaMKII causes cardiac sinus node dysfunction in mice. J Clin Invest. (2011) 121:3277–88. 10.1172/JCI57833
- 14.He BJ, Joiner ML, Singh MV, Luczak ED, Swaminathan PD, Koval OM, et al. Oxidation of CaMKII determines the cardiotoxic effects of aldosterone. Nat Med. (2011) 17:1610–28. 10.1038/nm.2506
- 15.Sanders PN, Koval OM, Jaffer OA, Prasad AM, Businga TR, Scott JA, et al. CaMKII is essential for the proasthmatic effects of oxidation. Sci Transl Med. (2013) 5:195ra97. 10.1126/scitranslmed.3006135
- 16.Anderson ME. Oxidant stress promotes disease by activating CaMKII. J Mol Cell Cardiol. (2015) 89:160–7. 10.1016/j.yjmcc.2015.10.014
- 17.Yao CX, Veleva T, Scott L, Jr, Cao SY, Li LG, Chen G, et al. Enhanced cardiomyocyte NLRP3 inflammasome signaling promotes atrial fibrillation. Circulation. (2018) 138:2227–42. 10.1161/circulationaha.118.035202
- 18.Liu Y, Lv HC, Tan R, An XB, Niu XH, Liu YJ, et al. Platelets promote Ang II (angiotensin II)-induced atrial fibrillation by releasing TGF-β1 (transforming growth factor-β1) and Interacting with fibroblasts. Hypertension. (2020) 76:1856–67. 10.1161/hypertensionaha.120.15016
- 19.Yu LM, Dong X, Zhao JK, Xu YL, Xu DY, Xue XD, et al. Activation of PKG-CREB-KLF15 by melatonin attenuates angiotensin II-induced vulnerability to atrial fibrillation via enhancing branched-chain amino acids catabolism. Free Radic Biol Med. (2022) 178:202–14. 10.1016/j.freeradbiomed.2021.11.043
- 20.Brundel B, Ai X, Hills MT, Kuipers MF, Lip GYH, de Groot NMS. Atrial fibrillation. Nat Rev Dis Primers. (2022) 8:21. 10.1038/s41572-022-00347-9
- 21.Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomstrom-Lundqvist C, et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European association for cardio-thoracic surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European society of cardiology (ESC) developed with the special contribution of the European heart rhythm association (EHRA) of the ESC. Eur Heart J. (2021) 42:373–498. 10.1093/eurheartj/ehaa612
- 22.Mayyas F, Alzoubi KH, Van Wagoner DR. Impact of aldosterone antagonists on the substrate for atrial fibrillation: aldosterone promotes oxidative stress and atrial structural/electrical remodeling. Int J Cardiol. (2013) 168:5135–42. 10.1016/j.ijcard.2013.08.022
- 23.Sygitowicz G, Maciejak-Jastrzebska A, Sitkiewicz DA. Review of the Molecular mechanisms underlying cardiac fibrosis and atrial fibrillation. J Clin Med. (2021) 10:4430. 10.3390/jcm10194430
- 24.Rabino M, Mallia S, Castiglioni E, Rovina D, Pompilio G, Gowran A. The endocannabinoid system and cannabidiol: past, present, and prospective for cardiovascular diseases. Pharmaceuticals (Basel). (2021) 14:936. 10.3390/ph14090936
- 25.Sugamura K, Sugiyama S, Nozaki T, Matsuzawa Y, Izumiya Y, Miyata K, et al. Activated endocannabinoid system in coronary artery disease and antiinflammatory effects of cannabinoid 1 receptor blockade on macrophages. Circulation. (2009) 119:28–36. 10.1161/circulationaha.108.811992
- 26.van Esbroeck ACM, Varga ZV, Di X, van Rooden EJ, Toth VE, Onodi Z, et al. Activity-based protein profiling of the human failing ischemic heart reveals alterations in hydrolase activities involving the endocannabinoid system. Pharmacol Res. (2020) 151:104578. 10.1016/j.phrs.2019.104578
- 27.Li XQ, Peng Z, Zhou YL, Wang J, Lin XY, Dong XR, et al. Quetiapine induces myocardial necroptotic cell death through bidirectional regulation of cannabinoid receptors. Toxicol Lett. (2019) 313:77–90. 10.1016/j.toxlet.2019.06.005
- 28.Li LL, Dong XR, Tu CY, Li XQ, Peng Z, Zhou YL, et al. Opposite effects of cannabinoid CB1 and CB2 receptors on antipsychotic clozapine-induced cardiotoxicity. Br J Pharmacol. (2019) 176:890–905. 10.1111/bph.14591
- 29.Duerr GD, Heinemann JC, Kley J, Eichhorn L, Frede S, Weisheit C, et al. Myocardial maladaptation to pressure overload in CB2 receptor-deficient mice. J Mol Cell Cardiol. (2019) 133:86–98. 10.1016/j.yjmcc.2019.06.003
- 30.Lee DI, Murninkas M, Elyagon S, Etzion Y, Anderson HD. Cannabinoid receptor agonist inhibits atrial electrical remodeling in a tachypaced Ex vivo rat model. Front Pharmacol. (2021) 12:642398. 10.3389/fphar.2021.642398
- 31.Meeran MFN, Al Taee H, Azimullah S, Tariq S, Adeghate E, Ojha S. beta-Caryophyllene, a natural bicyclic sesquiterpene attenuates doxorubicin-induced chronic cardiotoxicity via activation of myocardial cannabinoid type-2 (CB2) receptors in rats. Chem Biol Interact. (2019) 304:158–67. 10.1016/j.cbi.2019.02.028
- 32.Meeran MFN, Laham F, Azimullah S, Sharma C, Al Kaabi AJ, Tariq S, et al. beta-caryophyllene, a natural bicyclic sesquiterpene attenuates beta-adrenergic agonist-induced myocardial injury in a cannabinoid receptor-2 dependent and independent manner. Free Radic Biol Med. (2021) 167:348–66. 10.1016/j.freeradbiomed.2021.01.046
- 33.Gallelli CA, Calcagnini S, Romano A, Koczwara JB, de Ceglia M, Dante D, et al. Modulation of the oxidative stress and lipid peroxidation by endocannabinoids and their lipid analogues. Antioxidants (Basel). (2018) 7:93. 10.3390/antiox7070093
- 34.Schuttler D, Bapat A, Kaab S, Lee K, Tomsits P, Clauss S, et al. Animal models of atrial fibrillation. Circ Res. (2020) 127:91–110. 10.1161/CIRCRESAHA.120.316366
Associated Data
Supplementary Materials
Data Availability Statement
The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.